ABVC BioPharma appoints Leeds Chow as CFO and Principal Accounting Officer effective Sept 4, 2022

ABVC BIOPHARMA, INC.

Leeds Chow, 34, previously Controller since March 2021, appointed CFO and Principal Accounting Officer on Sept 4, 2022.
Mr. Chow has over 12 years experience in audit and financing, including family office and Hong Kong IPO advisory roles.
He holds a BA in Business Economics with Accounting Emphasis from the University of California, Santa Barbara.
No departure of prior CFO was announced; the board determined the reappointment to be in the Company's best interests.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Leeds Chow

Chief Financial Officer and Principal Accounting Officer

ABVC · ABVC BIOPHARMA, INC.

Effective: 2022-09-04
Filed: September 9, 2022, 7:59 PM ET

the Board has determined that it is in the best interests of ABVC BIOPHARMA, INC. (the “ Company ”) to reappoint Leeds Chow, age 34, the Company’s Controller, as Chief Financial Officer and Principal Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Leeds Chow was appointed as Chief Financial Officer and Principal Accounting Officer at ABVC BIOPHARMA, INC..

Action: appointed
Role: Chief Financial Officer and Principal Accounting Officer

Exact text from the filing

the Board has determined that it is in the best interests of ABVC BIOPHARMA, INC. (the “ Company ”) to reappoint Leeds Chow, age 34, the Company’s Controller, as Chief Financial Officer and Principal Accounting Officer.

View on SEC.gov

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-22-055075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.